Mojtaba Fathi
Overview
Explore the profile of Mojtaba Fathi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
213
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mennati A, Rostamizadeh K, Fathi M
Int J Biol Macromol
. 2025 Jan;
294:139334.
PMID: 39743068
Integrin αvβ3, a primary cell-adhesion receptor, plays a crucial role in various biological processes, including angiogenesis, pathological neovascularization, and tumor metastasis. Its expression increases during tumor angiogenesis. The insulin-like growth...
2.
Rezaei Arnesa A, Hajian S, Salemi Bazargani S, Salahshourifar I, Moghbelinejad S, Abdolvahabi Z, et al.
Iran J Kidney Dis
. 2024 Jun;
18(3):179-186.
PMID: 38904338
Introduction: Diabetic nephropathy is one of the most common severe symptoms of diabetes mellitus. Hyperglycemia can lead to tissue damage and inflammation due to mediators such as receptor for advanced...
3.
Pirsaraei V, Khodabandehloo H, Mousavi M, Zhiani M, Nazari S, Fathi M
Gene
. 2023 Nov;
900:148020.
PMID: 38000703
Objective: The adipokine Chemerin and the retinoic acid receptor responder 2 (RARRES2) gene have been associated with an increased incidence of obesity, insulin resistance, endothelial dysfunction, type 2 diabetes mellitus,...
4.
Shahidi S, Rostamizadeh K, Fathi M, Nedaei K, Ramazani A
BMC Complement Med Ther
. 2022 Dec;
22(1):340.
PMID: 36575448
Background: Colorectal cancer (CRC) is the second leading cause of cancer death. Although Regorafenib showed survival benefits in patients with CRC, reports imply the recurrence of malignant phenotype resulting from...
5.
Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, et al.
Diabetol Metab Syndr
. 2022 Nov;
14(1):170.
PMID: 36397128
Systemic inflammation and oxidative burden in patients with type 2 diabetes mellitus (T2DM) causes deleterious cardiovascular outcomes. We sought to investigate the clinical antioxidative and anti-inflammatory effects of empagliflozin. Platelet...
6.
Mousavi M, Abedimanesh N, Mohammadnejad K, Sharini E, Nikkhah M, Eskandari M, et al.
Mol Biol Rep
. 2022 Aug;
49(10):9345-9354.
PMID: 35988103
Background: Continuing hyperglycemia causes and exacerbate oxidative stress. Betanin as the principal pigment of red beet root has antioxidant, anti-inflammatory, and anti-diabetic properties. The purpose of this study was to...
7.
Hossein Heydari A, Fathi M, Heydari S, Esmaeil Heidari M
Cardiovasc Ther
. 2022 Apr;
2022:7014680.
PMID: 35414826
Introduction: Sphingosine 1 phosphate (S1P) is a product of the sphingosine kinase 1 (SphK1) enzyme. Increased S1P can lead to tissue fibrosis that is also one of the pathways for...
8.
Mennati A, Rostamizadeh K, Manjili H, Fathi M, Danafar H
Int J Biol Macromol
. 2022 Jan;
200:335-349.
PMID: 34999039
Insulin-like growth factor-1 receptor (IGF-1R) is expressed in malignant and normal breast tissue, and its intermittent activation by multiple IGF-1 signaling pathways leads to neoplasm cell proliferation, impaired apoptosis, increased...
9.
Gohari S, Reshadmanesh T, Khodabandehloo H, Fathi M, Ahangar H, Arsang-Jang S, et al.
BMC Cardiovasc Disord
. 2021 Jul;
21(1):318.
PMID: 34193056
Background: Recent trials have revealed that sodium-glucose co-transporter 2 inhibitors (SGLT2-i) are effective against hyperglycemia and also reduce micro- and macro-vascular complications in patients with type 2 diabetes mellitus (T2DM)....
10.
Zhiani M, Mousavi M, Rostamizadeh K, Pirizadeh R, Osali A, Mennati A, et al.
Am J Cancer Res
. 2021 May;
11(4):1170-1184.
PMID: 33948352
Colorectal cancer (CRC) is regarded as the third most common cancer worldwide. Although Regorafenib as a receptor tyrosine kinase inhibitor (RTKI) disrupts tumor growth and angiogenesis in metastatic CRC (mCRC)...